PDF herunterladen
Thromb Haemost 1997; 78(01): 652-655
DOI: 10.1055/s-0038-1657606
Plasminogen activator inhibitor I (PAI-1)
Schattauer GmbH Stuttgart

The Fat Mouse: A Powerful Genetic Model to Study Elevated Plasminogen Activator Inhibitor 1 in Obesity/NIDDM

J Loskutoff David
Department of Vascular Biology, The Scripps Research Institute, La Jolla, CA, USA
,
Samad Fahumiya
Department of Vascular Biology, The Scripps Research Institute, La Jolla, CA, USA
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
12. Juli 2018 (online)

Auch verfügbar auf
  als PDF herunterladen  Lizenzen und Reprints
 

  • References

  • 1 Larsson B. Obesity, fat distribution and cardiovascular disease. Int J Obesity 1991; 15: 53-57
    PubMedGoogle Scholar
  • 2 Bjömtorp P. Abdominal fat distribution and disease: An overview of epidemiological data. Ann Med 1992; 24: 15-18
    CrossrefPubMedGoogle Scholar
  • 3 DeFronzo RA, Ferrannini E. Insulin resistance: A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173-194
    CrossrefPubMedGoogle Scholar
  • 4 Loskutoff DJ. Regulation of PAI-1 gene expression. Fibrinolysis 1991; 5: 197-206
    PubMedGoogle Scholar
  • 5 Van Meijer M, Pannekoek H. Structure of plasminogen activator inhibitor 1 (PAI-1) and its function in fibrinolysis: An update. Fibrinolysis 1995; 9: 263-276
    PubMedGoogle Scholar
  • 6 Vague P, Juhan-Vague I, Aillaud MF, Badier C, Viard R, Alessi MC, Collen D. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. Metabolism 1986; 35: 250-253
    CrossrefPubMedGoogle Scholar
  • 7 Primrose JN, Davies JA, Prentice CRM, Hughes R, Johnston D. Reduction in factor VII fibrinogen and plasminogen activator inhibitor-1 activity after surgical treatment of morbid obesity. Thromb Haemost 1992; 68: 396-399
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 8 Sawdey MS, Loskutoff DJ. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo: Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-α, and transforming growth factor-β. J Clin Invest 1991; 88: 1346-1353
    CrossrefPubMedGoogle Scholar
  • 9 Choy LN, Rosen BS, Spiegelman BM. Adipsin and an endogenous pathway of complement from adipose cells. J Biol Chem 1992; 267: 12736-12741
    PubMedGoogle Scholar
  • 10 Spiegelman BM, Flier JS. Adipogenesis and obesity: Rounding out the big picture. Cell 1996; 87: 377-389
    CrossrefPubMedGoogle Scholar
  • 11 Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, Rabinowitz D, Lallone RL, Burley SK, Friedman JM. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 1995; 269: 543-546
    CrossrefPubMedGoogle Scholar
  • 12 Samad F, Loskutoff DJ. Tissue distribution and regulation of plasminogen activator inhibitor-1 in obese mice. Mol Med 1996; 2: 568-582
    PubMed
  • 13 Shimomura I, Funahashi T, Takahashi M, Maeda K, Kotani K, Nakamura T, Yamashita S, Miura M, Fukuda Y, Takemura K. et al. Enhanced expression of PAI-1 in visceral fat: Possible contributor to vascular disease in obesity. Nature Med 1996; 2: 800-803
    CrossrefPubMedGoogle Scholar
  • 14 Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue. Possible link between visceral fat accumulation and vascular disease. Diabetes. in press
    Google Scholar
  • 15 Juhan-Vague I, Roul C, Alessi MC, Ardissone JP, Heim M, Vague P. Increased plasminogen activator inhibitor activity in non-insulin-dependent diabetic patients: Relationship with plasma insulin. Thromb Haemostas 1989; 61: 370-373
    PubMedGoogle Scholar
  • 16 Asplund-Carlson A, Hamsten A, Wiman B, Carlson LA. Relationship between plasma plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: Studies in randomly selected normo-and hypertriglyceridaemic men. Diabetologia 1993; 36: 817-825
    CrossrefPubMedGoogle Scholar
  • 17 Reaven GM. Pathophysiology of insulin resistance in human disease. Physiol Rev 1995; 75: 473-486
    CrossrefPubMedGoogle Scholar
  • 18 Mykkänen L, Rönnemaa T, Mamiemi J, Haffher SM, Bergman R, Laakso M. Insulin sensitivity is not an independent determinant of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb 1994; 14: 1264-1271
    CrossrefPubMedGoogle Scholar
  • 19 Medvescek M, Keber D, Stegnar M, Borovnicar A. Plasminogen activator inhibitor 1 response to a carbohydrate meal in obese subjects. Fibrinolysis 1990; 04 (Suppl. 02) 89-90
    PubMedGoogle Scholar
  • 20 Vague PH, Juhan-Vague I, Alessi MC, Badier C, Valadier J. Metformin decreases the high plasminogen activator inhibition capacity, plasma insulin and triglyceride levels in non-diabetic obese subjects. Thromb Haemost 1987; 58: 326-328
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 21 Alessi MC, Juhan-Vague I, Kooistra T, Declerck PJ, Collen D. Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line Hep G2. Thromb Haemost 1988; 60: 491-494
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 22 Schneider DJ, Sobel BE. Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type I: Implications for vascular disease in hyperinsulinemic states. Proc Natl Acad Sci USA 1991; 88: 9959-9963
    CrossrefPubMedGoogle Scholar
  • 23 Jain SK, Nagi DK, Slavin BM, Lumb PJ, Yudkin JS. Insulin therapy in type 2 diabetic subjects suppresses plasminogen activator inhibitor (PAI-1) activity and proinsulin-like molecules independently of glycaemic control. Diabetic Medicine 1993; 10: 27-32
    CrossrefPubMedGoogle Scholar
  • 24 Grant PJ, Kruithof EKO, Felley CP, Felber JP, Backmann F. Short-term infusions of insulin, triacylglycerol and glucose do not cause acute increases in plasminogen activator inhibitor-1 concentrations in man. Clin Sci 1990; 79: 513-516
    CrossrefPubMedGoogle Scholar
  • 25 Landin K, Tengbom L, Chmielewska J, von Schenck H, Smith U. The acute effect of insulin on tissue plasminogen activator and plasminogen activator inhibitor in man. Thromb Haemostas 1991; 65: 130-133
    PubMedGoogle Scholar
  • 26 Vuorinen-Markkola H, Puhakainen I, Yki-Jarvinen H. No evidence for short-term regulation of plasminogen activator inhibitor activity by insulin in man. Thromb Haemostas 1992; 67: 117-120
    PubMedGoogle Scholar
  • 27 Potter van Loon BJ, De Bart ACW, Radder JK, Frölich M, Kluft C, Meinders AE. Acute exogenous hyperinsulinemia does not result in elevation of plasma plasminogen activator inhibitor-1 (PAI-1) in humans. Fibrinolysis 1990; 04 (Suppl. 02) 93-94
    PubMedGoogle Scholar
  • 28 Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-α: Direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91
    CrossrefPubMedGoogle Scholar
  • 29 Hotamisligil GS, Amer P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J Clin Invest 1995; 95: 2409-2415
    CrossrefPubMedGoogle Scholar
  • 30 van Hinsbergh VW, Kooistra T, van den Berg EA, Princen HM, Fiers W, Emeis JJ. Tumor necrosis factor increases the production of plasminogen activator inhibitor in human endothelial cells in vitro and in rats in vivo. Blood 1988; 72: 1467-1473
    PubMedGoogle Scholar
  • 31 Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425-432
    CrossrefPubMedGoogle Scholar
  • 32 Tartaglia LA, Dembski M, Weng X, Deng N, Culpepper J, Devos R, Richards GJ, Campfield LA, Clark FT, Deeds J. et al Identification and expression cloning of a leptin receptor, OB-R. Cell 1995; 83: 1263-1271
    CrossrefPubMedGoogle Scholar
  • 33 Nordt TK, Sawa H, Fujii S, Sobel BE. Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo. Circulation 1995; 91: 764-770
    CrossrefPubMedGoogle Scholar
  • 34 Alessi MC, Anfosso F, Henry M, Peiretti F, Nalbone G, Juhan-Vague I. Up-regulation of PAI-1 synthesis by insulin and proinsulin in HEP G2 cells but not in endothelial cells. Fibrinolysis 1995; 9: 237-242
    PubMedGoogle Scholar
  • 35 Samad F, Yamamoto K, Loskutoff DJ. Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo: Induction by tumor necrosis factor-α and lipopolysaccharide. J Clin Invest 1996; 97: 37-46
    CrossrefPubMedGoogle Scholar
  • 36 Sawdey M, Podor TJ, Loskutoff DJ. Regulation of type 1 plasminogen activator inhibitor gene expression in cultured bovine aortic endothelial cells: Induction by transforming growth factor-β, lipopoly saccharide, and tumor necrosis factor-α. J Biol Chem 1989; 264: 10396-10401
    PubMedGoogle Scholar
  • 37 Reilly CF, McFall RC. Platelet-derived growth factor and transforming growth factor-β regulate plasminogen activator inhibitor-1 synthesis in vascular smooth muscle cells. J Biol Chem 1991; 266: 9419-9427
    PubMedGoogle Scholar
  • 38 Lund LR, Riccio A, Andreasen PA, Nielsen LS, Kristensen P, Laiho M, Saksela O, Blasi F, Dano K. Transforming growth factor-β is a strong and fast acting positive regulator of the level of type-1 plasminogen activator inhibitor mRNA in WI-38 human lung fibroblasts. EMBO J 1987; 6: 1281-1286
    PubMedGoogle Scholar
  • 39 Thalacker FW, Nilsen-Hamilton M. Specific induction of secreted proteins by transforming growth factor-β and 12-0-tetradecanoyl-phorbol-13-acetate. Relationship with an inhibitor of plasminogen activator. J Biol Chem 1987; 262: 2283-2290
    PubMedGoogle Scholar
  • 40 Westerhausen DR, Hopkins WE, Billadello JJ. Multiple transforming growth factor-β-inducible elements regulate expression of the plasminogen activator inhibitor type-1 gene in Hep G2 cells. J Biol Chem 1991; 266: 1092-1100
    PubMedGoogle Scholar
  • 41 Fujii S, Sobel BE. Induction of plasminogen activator inhibitor by products released from platelets. Circulation 1990; 82: 1485-1493
    CrossrefPubMedGoogle Scholar
  • 42 Samad F, Yamamoto K, Pandey M, Loskutoff DJ. Elevated expression of transforming growth factor-β in adipose tissue from obese mice. Mol Med 1997; 03: 36-47
    PubMedGoogle Scholar
  • 43 Keeton M, Eguchi Y, Sawdey M, Ahn C, Loskutoff DJ. Cellular localization of type 1 plasminogen activator inhibitor messenger RNA and protein in murine renal tissue. Am J Pathol 1993; 142: 59-70
    PubMedGoogle Scholar
  • 44 Lundgren CH, Brown SL, Nordt TK, Sobel BE, Fujii S. Elaboration of type-1 plasminogen activator inhibitor from adipocytes: A potential pathogenetic link between obesity and cardiovascular disease. Circulation 1996; 93: 106-110
    CrossrefPubMedGoogle Scholar